Psychedelic Science 2023

Be Part of

        the Breakthrough

Presented by

Panel discussion: The state of ketamine-assisted therapy


Panel discussion: The state of ketamine-assisted therapy

Ketamine, an essential medicine according to the World Health Organization, is a long-established anesthetic with global use in surgery and pain management. While its potential for rapid antidepressant effects were documented more than 20 years ago, its off-label use as a treatment for depression and other mental health disorders have only recently become widely available, and the topic of popular conversation. Due to its status as a Schedule III drug for anesthetic purposes, ketamine is the first "psychedelic" drug to be widely available in the US. While its potential for alleviating the symptoms of depression is significant and documented, and research continues to grown regarding its use for other indications, there remain many questions about its potential for abuse, long-term safety and efficacy, and the variable quality of care in a lightly regulated market. Join us for a discussion about state of ketamine-assisted therapy.

Share: Panel discussion: The state of ketamine-assisted therapy


Already Registered?

If you already registered for the in-person portion of the Psychedelic Science 2023 conference, get immediate access to PS2023: The Virtual Trip by logging in with the email address you used when signing up for the conference. We’ll email you a login link—no password necessary!

Need to Register?

If you are not yet registered for Psychedelic Science 2023, you can sign up for PS2023: The Virtual Trip access by creating an account.